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Since Greenspan and Canellos evaluated combination
chemotherapy for metastatic breast cancer there have been
continued changes to the various combinations used to treat
advanced breast cancer (Greenspan, 1966; Canellos et al, 1976).
Combination chemotherapy for metastatic breast cancer can
achieve tumour response rates of between 30 and 60%
(Mouridsen, 1992; Honig, 1996). However, improvements in
long-term remissions and overall survival have been difficult to
achieve and thus the challenge in advanced breast cancer is to
develop regimens that have low subjective toxicity whilst main-
taining clinical efficacy.
Cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in
its range of schedules is often considered a standard regime for
first-line treatment of metastatic breast cancer with response rates
between 30 and 60% (Bull et al, 1978; Tormey et al, 1982; Aisner
et al, 1987; Cummings et al, 1995). Methotrexate, mitoxantrone
and mitomycin (MMM) is a combination which has shown to be
as active but less emetogenic than vincristine, adriamycin and
cyclophosphamide regime (VAC) (Powles et al, 1991). When
compared to CMF it was similarly well tolerated and with a
comparable efficacy and toxicity spectrum (Jodrell et al, 1991).
Both of these studies (Jodrell et al, 1991; Powles et al, 1991),
however, showed significantly worse haematological toxicity
occurring in patients on MMM regimes, with thrombocytopenia
occurring in 34% of patients receiving MMM compared to 14% on
CMF. In the MMM/VAC study, myelosuppression was greater in
patients receiving MMM compared to those on VAC at day 21, i.e.
the time for next treatment. There was also significantly greater
grade 3 and 4 leucopenia and thrombocytopenia at day 21
following MMM than after the MM part of the regime, i.e. after
only methotrexate and mitoxantrone had been administered. This
finding led us to compare MMM with the MM regimen, since it
was thought that mitomycin C may have been responsible for most
of the haematological toxicity. No significant difference in objec-
tive response was found between these two regimes, which were
well tolerated, but significantly less haematological toxicity and
fewer dose delays and reductions were evident with MM (Stein
et al, 1992).
Since the MM chemotherapy regime was relatively well toler-
ated, we decided to carry out a randomized trial to compare MM
with CMF, incorporating comparisons of quality of life and side-
effects on treatment.
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Summary One hundred and sixteen patients with locally advanced or metastatic breast cancer were randomized to receive CMF
(cyclophosphamide 600 mg m–2 day 1 and 8 i.v., 5-fluorouracil 600 mg m–2 day 1 and 8 i.v.,, methotrexate 40 mg m–2 day 1 and 8 i.v., monthly
for 6 cycles) or MM (methotrexate 30 mg m–2, mitoxantrone 6.5 mg m–2, both i.v. day 1 3-weekly for 8 cycles) as first line treatment with
chemotherapy. Objective responses occurred in 17 patients out of 58 (29%) who received CMF and nine out of 58 (15%) who received MM;
95% confidence interval for difference in response rates (–1%–29%), P = 0.07. No statistically significant differences were seen in overall
survival or time to progression between the two regimes although a tendency towards a shorter progression time on the MM regime must be
acknowledged. There was, however, significantly reduced haematological toxicity (P < 0.001) and alopecia (P < 0.001) and fewer dose
reductions and delays in patients randomized to MM. No statistically significant differences were seen between the two regimes in terms of
quality of life (QOL). However, some association between QOL and toxicity was apparent overall with pooled QOL estimates tending to
indicate a worsening in psychological state with increasing maximum toxicity over treatment. Despite the fact that results surrounding
response rates and time to progression did not reach statistical significance, their possible compatibility with an improved outcome on CMF
treatment must be borne in mind. However, MM is a well-tolerated regimen with fewer side-effects than CMF, which with careful patient
management and follow-up, therefore, may merit consideration as a first-line treatment to palliate patients with metastatic breast cancer who
are infirm or elderly.
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PATIENTS AND METHODS
Patient eligibility
All patients with cytologically or histologically proven locally
advanced or metastatic breast cancer requiring treatment with
cytotoxic chemotherapy were considered for entry into the trial.
There were no age limits set for trial eligibility. Patients who had
had prior treatment with any chemotherapeutic agents for locally
advanced or metastatic breast cancer were excluded. Adjuvant
chemotherapy had to have been completed more than 2 years prior
to entry. Patients had to have measurable or evaluable lesions with
documented progression within 2 months before entry into the
study. Prior radiation to any of the present areas of measurable or
evaluable disease also excluded the patient from the trial. Patients
with psychiatric or addictive disorders, which would preclude
obtaining informed consent or compliance with the quality of life
studies, were considered ineligible. Further exclusion criteria were
as follows: cardiac failure or significant dysrythmia, severe renal
(blood urea nitrogen > 18 mmol l–1) or hepatic impairment
(bilirubin > four times normal), impaired bone marrow function
(white cell count (WBC) 3.5 ´ 109 l–1 or platelets < 150 ´ 109 l–1),
simultaneous endocrine therapy or endocrine therapy within 3
weeks of entry (when withdrawal response was considered to be
possible) and evidence of an active second malignancy. The trial
protocol was accepted by the ethical review board for this institu-
tion. All patients gave written consent to take part in the study.
Treatment
The treatment schedules were as follows: the CMF regimen
consisted of cyclophosphamide at a dose of 600 mg m–2,
methotrexate at 40 mg m–2 and 5-fluorouracil at 600 mg m–2, all
administered intravenously (i.v.) on days 1 and 8. The cycle was
repeated every 4 weeks for a total of six cycles. The MM regimen
consisted of methotrexate at a dose of 30 mg m–2 and mitoxantrone
at 6.5 mg m–2, both administered i.v. on day 1, repeating the cycle
every 3 weeks for a total of eight cycles. Folinic acid was not used
routinely. Dose modification was carried out for both CMF and
MM regimens according to the levels of WBC and platelets. One
hundred per cent of the dose was given if levels were WBC
> 3.0 ´ 109 l–1 and platelets > 100 ´ 109 l–1. If the WBC level was
2.5–3.0 ´ 109 l–1 but platelets remained over 100 ´ 109 l–1, the
patient received 75% of the full dose. If the WBC level was
< 2.5 ´ 109 l–1 or platelets < 100 ´ 109 l–1 a delay of 1 week was
recommended. If blood urea was > 12 mmol l–1, MM
chemotherapy was not given. Methotrexate dose was reduced and
folinic acid rescue given if the urea was between 9 and 12 mmol
l–1. MM was also withheld if serum bilirubin > 30 mmol l–1 and
AST were twice the upper limit of normal. Mitoxantrone dose
was reduced if there was any evidence of impaired hepatocellular
function. To prevent nausea and vomiting, dexamethasone (12 mg
day–1) and domperidone (60 mg day–1) was suggested for all
patients. If this failed, the addition of 5HT3 receptor antagonist to
the dexamethasone was recommended.
Study parameters and toxicity assessment
Patients were fully staged prior to randomization by clinical
examination, chest X-ray, full blood count, serum urea, calcium,
electrolytes and liver function tests. Liver ultrasound (optional if
liver function tests were normal and liver was not palpable) and a
limited skeletal survey consisting of lateral X-rays of the skull,
cervical/lumbar spine and AP of the pelvis were also performed.
Isotopic bone scans, computerized tomography scans and lung
function tests were optional. An initial assessment was completed
pre-treatment for each patient recording age, body surface area,
menopausal status, performance status, disease-free interval and
previous adjuvant chemotherapy/hormone therapy. Disease
assessment was also carried out prior to initial chemotherapy
recording haematology and sites and size of assessable disease.
Patients encompassing the range of Karnofsky scores (EORTC,
1996) were included in the study, but this information was not
recorded prospectively. However, only five patients were entered
who had required hospitalization.
Response was defined using the UICC criteria (Hayward et al,
1977). Details of treatment, response, toxicity and clinical assess-
ments of disease were made when chemotherapy was adminis-
tered, i.e. 3-weekly for MM and 4-weekly for CMF. Radiological
reassessment was carried out at week 12 (prior to course four
CMF/course five MM) and week 28 (i.e. 4 weeks after completion
of chemotherapy) or, if necessary, on early withdrawal. Toxicity
was documented before giving each chemotherapy and was then
recorded at weeks 12 and 24 as the worst since last assessment
according to WHO criteria (WHO, 1979). Nausea/vomiting, diar-
rhoea, alopecia, skin rash, ‘other toxicity’ and haematology were
all recorded specifically. After completion of treatment, patient
follow-up continued at 6-monthly intervals, dates and causes of
death being recorded where necessary.
Quality of life
Quality of life (QOL) was measured according to the Hospital
Anxiety and Depression Scale (HADS) (Zigmond and Snaith,
1983) and the Rotterdam Symptom CheckList (RSCL) (De-Haes
et al, 1990), along with three additional ‘patient satisfaction’ ques-
tions asking, ‘How satisfactory do you feel your hospital treatment
has been?’, ‘What quality of life have you enjoyed in the past
month?’ and ‘What quality of life did you enjoy before your
illness?’. These last three questions were all measured on a four-
point scale, possible responses to each being: extremely satisfac-
tory, satisfactory, unsatisfactory or extremely unsatisfactory.
Patients taking part in the QOL study were expected to complete a
total of three assessments during their clinic visits pretreatment, at
week 12 and week 24, or if appropriate on withdrawal from treat-
ment if the patient consented. All available data were initially
tabulated according to assessment visit but the main QOL analyses
were based on patients having at least two assessments (i.e. an
initial assessment pretreatment plus one other).
The most dissatisfaction noted during treatment for each of the
three ‘patient satisfaction’ questions was compared with that noted
at initial assessments. Data from the HADS and RSCL scales were
analysed both as continuous scores and also categorized according
to level of severity. HADS anxiety and depression were categorized
as clinically abnormal state present (score 11+), borderline (8–10)
or absent (0–7). The RSCL psychological scale was categorized as
high (score 18+), borderline (14–17) or low (0–13) and the physical
scale categorized similarly but with score groups 28+, 24–27, 0–23.
Change in score or category from initial assessment to each treat-
ment visit was calculated along with change to the maximum
(i.e. most severe) score or category recorded during treatment.
Combined analyses (not split by treatment group) were also used to318 C Harper-Wynne et al
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Table 2 Best overall response
CMF (n = 58) MM (n = 58)
CR 2 (3%) 3 (5%)
PR 15 (26%) 6 (10%)
NC 15 (26%) 15 (26%)
PD 14 (24%) 25 (43%)
2+ courses of treatment given 11 21
<2 courses of treatment given 3 4
Not evaluable 12 (21%) 9 (16%)
assess overall whether maximum toxicity during treatment was
associated with HADS/RSCL quality of life score. Similar associa-
tions with the change in HADS/RSCL scores from initial assess-
ment to that of maximum toxicity were also evaluated. For these
analyses, if maximum toxicity was recorded at more than one visit,
average QOL scores were calculated and, for change analyses, the
difference between the average and initial assessment taken.
Statistical methods
Data are presented as n (%) or median (range) as appropriate. Chi-
squared tests were used to investigate associations between
categorical variables. Linear trends in QOL scores across
maximum toxicity levels were investigated using one-way
analysis of variance. Log-rank tests (Peto et al, 1977) were used to
compare the survival experience and time to progression, from
randomization, between the two regimes. All patients, including
those considered to be unevaluable for response, remained in the
statistical analysis when comparing response rates between the
two regimes and thus summary statements of response rates
include all patients in the denominator unless otherwise indicated.
Statistical analyses were conducted using SPSS version 4.1, apart
from those assessing survival (for which in house, Fortran-based,
software was used).
RESULTS
One hundred and sixteen patients were randomized (58 to CMF
and 58 to MM), between January 1992 and December 1996 all
from Charing Cross Hospital, London. One patient was lost to
follow-up after having received one course of treatment when she
returned to Australia (see trial profile).
Initial treatment forms were received from all patients, and
patient characteristics are summarized in Table 1. The median age of
the patients randomized was 59 years (range 28–84). The majority
(86%) were post-menopausal. Ninety seven per cent of primary
Table 1 Patient characteristics
CMF MM Total
(n = 58) (n = 58) (n = 116)
Age
<35 0 (–) 3 (5%) 3 (2%)
35–<45 6 (10%) 7 (12%) 13 (11%)
45–<55 14 (24%) 8 (14%) 22 (19%)
55–<65 25 (43%) 19 (33%) 44 (38%)
65–<75 9 (16%) 11 (19%) 20 (17%)
75–<85 4 (7%) 10 (17%) 14 (12%)
Median (range) 58 (37–80) 61 (28–84) 59 (28–84)
Menopausal status
Premenopausal 6 (10%) 10 (17%) 16 (14%)
Post-menopausal 52 (90%) 48 (83%) 100 (86%)
Histology – primary tumour type
Infiltrating ductal 49 (96%) 48 (86%) 97 (97%)
Infiltrating ductal & lobular 2 (4%) 1 (2%) 3 (3%)
N/K 7 9 16
Sites of metastatic diseaseb
Breast/chest wall 24 (41%) 23 (40%) 47 (41%)
Lymph nodes 10 (17%) 15 (26%) 25 (22%)
Liver 19 (33%) 22 (38%) 41 (35%)
Bone 34 (59%) 31 (53%) 65 (56%)
Previous adjuvant CT 7 (12%) 5 (7%) 12 (10%)
Previous radiotherapy 43 (74%) 39 (67%) 82 (71%)
Previous adjuvant tamoxifen or 43 (74%) 39 (68%) 82 (71%)
endocrine therapya
Previous CT for advanced disease 1 (2%) 1 (2%) 2 (2%)
aOne MM patient not known; bsites not mutually exclusive.
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tumours were infiltrating ductal carcinoma. Most patients had
multiple sites of metastatic disease. Over half had bone metastases,
with other main sites comprising breast/chest wall, lymph nodes and
liver (see Table 1). Ten per cent of patients had previous adjuvant
chemotherapy, whereas 71% received previous radiotherapy and
71% previous adjuvant tamoxifen or endocrine therapy.
Twenty-one patients (18%) (12 CMF/9 MM) were deemed
unevaluable for overall response assessment for the following
reasons: two patients (CMF) were incorrectly randomized having
previously received chemotherapy for advanced breast cancer and
one patient (MM) had grossly abnormal liver function tests. Five
patients died before treatment was given (all CMF). Seven patients
died after one course of treatment prior to assessment of response
(three CMF, four MM), and a further patient (CMF) stopped treat-
ment due to toxicity after one course and changed treatment before
assessment of response. Of the remaining five patients, one MM
patient had a treatment deviation, one MM patient had a revised
diagnosis of metastatic small bowel carcinoma, two MM patients
had no assessable disease and one patient (CMF) stopped treat-
ment with an intercurrent illness.
No statistically significant differences were seen between the
two treatment groups with regards to survival (Figure 1), with
45/58 (78%) patients randomized to CMF and 41/58 (72%) of those
randomized to MM being known to have died during the course of
the study. Time to progressive disease (Figure 2) was also not found
to be significantly different between the two treatment groups
although there was a tendency towards a shorter time to progres-
sion on the MM regimen, with median time to progression in CMF
patients was days compared to 109 days for patients randomized to
MM, suggesting that MM was less effective than CMF (log-rank, P
= 0.2, see Discussion). Proportionality of hazards across time was
investigated further given the shape, in particular, of the time to
progression curves; the log-rank test being perhaps not the most
powerful statistical test to use in situations of non-proportionality.
However, when tested, formally, any deviation was not found to be
severe enough to reach statistical significance.
On an intention to treat basis, lower percentages of patients
receiving MM achieved a complete/partial response (15%, 9/58)
compared to those on the CMF regimen (29%, 17/58) (95% confi-
dence interval for difference in response rates –1%–29%, P = 0.07,
Table 2). Of the 95 patients evaluable for response, 37% of CMF
patients achieved a complete/partial response compared to 18% of
those receiving MM. Thus, there was a lower response rate for
patients receiving MM chemotherapy.
Reasons for treatment being stopped were similar in the two
treatment groups and were primarily due to progressive disease or
Table 3 Experience of toxicity over treatment (patients with toxicity data available)
WHO CMF (n = 48) MM (n = 47) P-value for
Worst experience of: grading trend (c2
1)
Nausea and vomiting
None 0 19 (39%) 26 (55%)
Nausea 1 12 (25%) 9 (19%)
Transient vomiting 2 8 (17%) 10 (21%)
Vomiting – needed treatment 3 8 (17%) 1 (2%)
Intractable vomiting 4 1 (2%) 1 (2%) 0.08
Diarrhoea
None 0 39 (81%) 44 (94%)
Transient < 2 days 1 5 (10%) 2 (4%)
Tolerable > 2 days 2 4 (8%) 1 (2%) 0.07
Alopecia
No change 0 33 (69%) 43 (91%)
Minimal hair loss 1 5 (10%) 3 (6%)
Moderate patchy loss 2 6 (13%) 1 (2%)
Complete – reversible 3 4 (8%) 0 (–) 0.002
Anaemia (Hb)
11 + g/dl 0 24 (50%) 32 (68%)
9.5–10.9 g/dl 1 18 (38%) 9 (19%)
8.0–9.4 g/dl 2 4 (8%) 5 (11%)
6.5–7.9 g/dl 3 2 (4%) 1 (2%) 0.2
Skin rash
No change 0 47 (98%) 46 (98%)
Erythema 1 0 (–) 1 (2%)
Dry desquamation 2 1 (2%) 0 (–) 0.7
Leucopenia (WBC)
>4´109/l 0 14 (29%) 19 (41%)
3–3.9´109/l 1 8 (17%) 14 (30%)
2–2.9´109/l 2 14 (29%) 11 (24%)
1–1.9´109/l 3 7 (14%) 0 (–)
<1´109/l 4 5 (10%) 0 (–) 0.001
N/K 0 1
Platelets:
>100´109/l 0 42 (87%) 41 (91%)
75–99´109/l 1 3 (6%) 3 (7%)
50–74´109/l 2 1 (2%) 1 (2%)
25–49´109/l 3 0 (–) 0 (–)
0–24´109/l 4 2 (4%) 0 (–) 0.4
N/K 0 2320 C Harper-Wynne et al
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death. Twenty-nine patients receiving CMF (50%) and 18 MM
(31%) completed treatment as per protocol (P = 0.04). Of the
patients who completed treatment, 9/29 (31%) of those random-
ized to CMF completed without any deviations from treatment
compared to 11/18 (61%) of those randomized to MM (P = 0.04).
In the 20 CMF patients who had treatment deviations, 50% of
deviations were as a result of haematological toxicity compared to
none in the seven MM patients. Two toxic deaths were recorded,
both patients receiving CMF, one being a result of haematological
toxicity.
Toxicity data during treatment was available on 95 patients (48
CMF, 47 MM; Table 3). There was no evidence, in terms of statis-
tical significance, of differences between the two regimes with
regards to patient experience of nausea/vomiting, diarrhoea,
anaemia, or skin rash. However, evidence of less severe
leucopenia was apparent in MM patients (c2
1 (trend), P = 0.001),
with no patients recording WBC levels < 2 ´ 109 l–1 (grade 3 or
above) compared to 12 (25%) patients receiving CMF. Five
episodes of neutropenic sepsis were seen in patients receiving
CMF compared with no patients in the MM arm of the study.
There was also evidence for less alopecia on the MM regimen
(P = 0.002). Only three MM patients (6%) recorded minimal hair
loss (grade 1) and 1 (2%) moderate patchy loss, with the remainder
(91%) having no change. In comparison, 15 (31%) patients
receiving CMF recorded some level of alopecia. Five of these had
minimal hair loss (grade 1), six moderate patchy loss (grade 2) and
four complete (reversible – grade 3). Severity of ‘other toxicity’
reported was very similar between the two treatment groups, the
more commonly reported forms being mucositis/oral discomfort
(most often at grade 1 or 2 severity), fatigue/malaise/headaches
and constipation, the latter two usually reported at grade 1 severity.
Due to reduced patient numbers following early study termination
(see further comment in Discussion), comprehensive evaluation of
QOL data was not possible with any satisfactory level of power.
However, data available were investigated in an attempt to establish
whether any general trends were apparent. Eighty-eight patients
were well enough to complete the first QOL assessment. However,
overall 28 patients completed only one assessment, 25 completed
two and only 35 (26 CMF and nine MM) had the desired complete
set at initial assessment, 12 weeks and 24 weeks. One patient
completed two QOL assessments at 12 weeks and 24 weeks, but was
thereafter unevaluable in terms of change from initial visit, leaving
59 patients evaluable with regards to change scores.
Of the 28 patients who only completed one QOL assessment, 19
did not complete the 12-week assessment as they had come off
treatment because of toxicity, progressive disease or death. The
remaining nine patients failed to complete the questionnaire, either
because they refused (six) or did not receive the form (three).
Analysis of QOL data by assessment visit showed neither
evidence of differences between treatment groups, nor of differ-
ences between weeks 12 and 24 or from patients withdrawing
early. The ‘on treatment data’ responses obtained were therefore
combined across visits into summary measures of ‘most dissatis-
faction’ and maximum score and evaluated in terms of change
from initial assessment.
HADS and RSCL scales did not reveal evidence of differences
between the two groups in terms of maximum change from initial
assessment, whether analysed by categorical change in state or
using the data in continuous form. Only five patients (three CMF,
two MM) showed any sign of being dissatisfied with the hospital
treatment they had received, and no statistically significant differ-
ences were seen between the two regimes in terms of maximum
change in satisfaction or QOL from initial assessment, results thus
reflecting results from HADS and RSCL scales. However, some
association between QOL and maximum toxicity experience was
apparent overall, in the 59 patients with two or more QOL assess-
ments, with mean changes in HADS anxiety/depression and RSCL
psychological scores from initial assessment to the visit at which
maximum toxicity was noted all showing some tendency to
increase with rising maximum toxicity (P = 0.01, P = 0.03, P =
0.05 respectively; Figures 3 and 4).
We carried out an analysis of the treatment patients received
after CMF or MM chemotherapy. In the CMF group, 21 patients
had one further course and five had two further forms of
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chemotherapy: 12 received epirubicin and five Taxotere; nine
patients had MM. In the MM group, 21 patients had further
treatment with chemotherapy: five received epirubicin and five
Taxotere; five patients had CMF. Six received 5-fluorouracil,
epirubicin and cyclophosphamide chemotherapy.
DISCUSSION
Our study shows that the methotrexate/mitoxantrone (MM)
regimen is likely to be less active than CMF, but MM may be a
useful first-line chemotherapy schedule for the palliation of
patients with advanced or metastatic breast cancer in whom side-
effects should be avoided. First, no patients receiving MM
suffered from severe leucopenia (WBC < 2 ´ 109 l–1), compared
to 12 on CMF. Secondly, only 8% of MM patients developed
alopecia, with only a single MM patient complaining of moderate
hair loss compared to 31% of CMF patients. Potential drawbacks
of the MM regimen include (a) a reduced response rate, and (b) a
shorter time to progression overall, although in this randomized
study no statistically significant differences were found in
response rate, survival or progression free survival between MM
and CMF (Table 2, Figures 1 and 2). We also observed that 55% of
CMF and 41% of MM patients achieved either CR/PR/NC and the
number of patients who died shortly after chemotherapy because
of progressive disease was similar in both treatment groups. These
features suggest that, provided the chemotherapy is substituted for
a more aggressive regimen on clinical evidence of disease progres-
sion, the MM regimen does not jeopardize survival.
Although no significant differences in response rate, survival or
times to progression were found in this study, it must be noted that
statistical power was low. The trial was originally planned to
recruit 326 patients to give an 80% power (two-sided a = 0.05) to
detect a 15% absolute difference in response rates assuming a 30%
response in patients treated with MM. However, due to poor
accrual, the study was prematurely terminated on the advice of an
Independent Data Monitoring Committee.
Our overall response rate with CMF compares well with the
protocol used by Tannock et al (1998). However, those authors
highlight the variations that exist in response rates between institu-
tions using similar regimes and comment that they are often not
meaningful as patient selection and treatment policy differ, such as
in the use of endocrine therapy as first-line in metastatic disease.
This is exemplified by comparing this study, in which the patients
were heavily pretreated with hormonal agents (74% and 64% with
CMF, and 68% and 60% with MM in the adjuvant and advanced
treatment settings respectively), with other CMF trials which have
either not recorded previous hormone treatment, not specified in
which setting it was previously given, or had lower numbers of
previously treated patients (Bull et al, 1978; Tormey et al, 1982;
Aisner et al, 1987; Cummings et al, 1995). Another trial
comparing CMF with MMM did have hormone pretreatment
levels of 70%, i.e. approaching our own, and had a CMF response
rate of 60%, but adjuvant chemotherapy was an exclusion (Jodrell
et al, 1991).
We obtained a comparable median survival with both regimes in
our group of patients and the survival observed is similar to other
recent studies (Clavel and Catimel, 1993, Stewart et al, 1997). It
was our practice, during the course of the study, to treat patients
with a sequence of an anthracycline, and subsequently a taxane
after relapse or failure to respond to CMF or MM. This is a prac-
tice that is followed in many cancer centres. At present the aim of
most trials in advanced breast cancer involving the use of newer
agents, e.g. the taxanes and high-dose trials is to improve response
and, hopefully, also survival. In the case of advanced breast cancer
there is little evidence that improvement in CR rate will manifest
in significantly increased long-term survival and metastatic breast
cancer remains essentially incurable. More recent trials, however,
have shown some statistical response advantage with anthra-
cycline containing regimes, but not all have shown a statistical
survival or response duration advantage (Muss et al, 1978;
Brickner et al, 1984; Tormey et al, 1984; Smalley et al, 1983).
Recently A’Hern et al (1993) used summary statistics on the trials
that included doxorubicin in the Cooper-type regimes (Cooper et
al, 1969) to arrive at a median survival improvement of a fifth.
Such small improvements in survival and responses do not neces-
sarily translate into enhanced QOL and other studies have demon-
strated that there is no conclusive evidence of survival advantage
although response rates were improved (Gradishar et al, 1996).
Our study is also one of a small number of breast cancer trials to
examine QOL using standardized scales, although our experience
underlines the difficulties in successfully obtaining serial QOL
estimates in this patient population. A recent study compared QOL
in intermittent and continuous administered chemotherapy sched-
ules. Although survival was similar in both arms of the study, QOL
was better in patients receiving treatment continuously compared
to those receiving it in 3-monthly blocks of treatment (Coates et al,
1987). Indeed, we could find no recent breast cancer trial that has
used the HADS and RSCL scales which have been recommended
by Maguire and Selby, 1989). Although we were not in a strong
position to evaluate differences between the two groups because of
low power due to premature study termination and the small
number of patients who were able to complete the QOL study, we
were able to show trends towards deteriorating QOL with rising
maximum toxicity overall. Other authors have discussed the rela-
tionship between toxicity and QOL, reporting that the latter is
usually although not always related to the former (Payne, 1992).
In conclusion, the MM regime is a regime which could be
considered to be better tolerated than the standard CMF regimen
for metastatic breast cancer. The limitations of this trial must be
acknowledged, but with careful patient management there may be
potential for MM to be considered as a first-line treatment, partic-
ularly in those who are frail or for those in whom leucopenia is
undesirable.
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